Latest Ratios: P/E Ratio -0.2x · EV/EBITDA N/A · ROE -1625.1%. (2014–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3M | $3M | $61M | $75M | $25M | $51M | $11M | $13M | — | — | — |
| Enterprise Value | $3M | $3M | $59M | $72M | $18M | $45M | $9M | $8M | — | — | — |
| P/E Ratio → | -0.20 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | 21.52 | 6.35 | 1.27 | 4.24 | 2.76 | 2.33 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -1625.1% | -1625.1% | -134.5% | -59.6% | -64.1% | -93.4% | -99.7% | -81.6% | -1143.5% | -88.5% | -3985.2% |
| ROA | -343.5% | -343.5% | -110.8% | -55.5% | -61.0% | -87.4% | -85.7% | -63.1% | -482.6% | -81.3% | -288.0% |
| ROIC | — | — | -158.2% | -69.2% | -85.3% | -154.2% | -253.8% | -852.3% | — | — | — |
| ROCE | -1355.2% | -1355.2% | -137.7% | -63.7% | -65.2% | -93.1% | -100.4% | -120.5% | -1143.5% | -87.7% | -3985.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.04 | 0.00 | 0.00 | 0.01 | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.78 | -0.24 | -0.35 | -0.54 | -0.55 | -0.81 | — | -1.05 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -65.39 | -65.39 | — | — | -2015.60 | — | — | — | — | -110.85 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.17 | 0.17 | 1.44 | 8.51 | 18.36 | 19.61 | 4.65 | 4.35 | 0.75 | 19.51 | 0.21 |
| Quick Ratio | 0.17 | 0.17 | 1.44 | 8.51 | 18.36 | 19.61 | 4.65 | 4.36 | 0.75 | 19.51 | 0.21 |
| Cash Ratio | 0.15 | 0.15 | 1.32 | 8.08 | 17.57 | 19.13 | 4.27 | 4.33 | 0.63 | 19.46 | 0.21 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $2M | $10M | $9M | $1M | $622497 | $123588 | $72415 | $42584 | $36385 | $31833 |
Imminent liquidity and dilution
As reported in financial statements, Artelo's lack of revenue renders traditional valuation metrics like P/E or EV/EBITDA inapplicable, forcing investors to rely on speculative net present value models that are currently heavily discounted due to the company's precarious $600,000 cash position and ongoing clinical development risks.
The absence of meaningful valuation multiples suggests that the market is pricing the firm purely as a binary option on its clinical pipeline rather than a going concern. Investors should monitor whether the current market capitalization reflects the high probability of significant equity dilution required to sustain operations beyond the immediate term.
Based on reported figures, Artelo's ROIC has consistently remained in negative territory, reaching -5.7% in 2025Q1, which highlights the company's inability to generate returns on invested capital while it remains in the high-cost, pre-revenue phase of its clinical development cycle.
The persistent decay in returns on capital is a structural feature of a firm that consumes cash to fund R&D without a commercial product to offset expenses. This trend warrants further investigation into whether the current allocation of capital across multiple pipeline assets is efficient or if it is merely accelerating the depletion of shareholder equity.
According to recent SEC filings, the company's current ratio has deteriorated from 11.36 in 2024Q1 to a critical 1.79 in 2026Q1, signaling a rapid erosion of the firm's ability to meet short-term obligations as cash reserves dwindle to a reported $600,000.
The sharp decline in liquidity ratios suggests that the company is approaching a point where it may be unable to fund its ongoing clinical trials without immediate external capital. Investors should monitor the potential for a distressed financing event, which would likely result in substantial dilution for existing shareholders.
As indicated by the company's financial statements, Artelo maintains a low debt-to-equity ratio of 0.11 as of 2026Q1, suggesting that while the firm is financially distressed, its primary risk is not insolvency from debt service but rather the exhaustion of cash to fund research operations.
The low leverage profile is typical for early-stage biotech firms that rely on equity rather than debt to fund development. However, the lack of interest coverage, evidenced by a -22.85 ratio, confirms that the company is not generating the operating income necessary to support even modest debt obligations.
The most commonly misapplied metric for Artelo is the Price-to-Book ratio, which obscures the reality that the company's book value is largely composed of intangible assets and goodwill that may hold little liquidation value in the event of a failed clinical trial or insolvency.
Investors should instead focus on the 'Cash Runway' metric, calculated by dividing the current cash balance by the monthly burn rate, as this provides a more accurate assessment of the company's survival horizon. Relying on book value in a pre-revenue biotech context may lead to a false sense of security regarding the firm's underlying asset base.
Includes 30+ ratios · 12 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ARTL stock.
Artelo Biosciences, Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
Artelo Biosciences, Inc.'s return on equity (ROE) is -1625.1%. The historical average is -91.9%.
Based on historical data, Artelo Biosciences, Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.